Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead President Thinks Firm Is Safe From Pfizer/GSK HIV Joint Venture - For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

Near term, Gilead’s Milligan doesn’t see “anything really competitive.”

You may also be interested in...



ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III

Phase II results presented at International AIDS Society meeting fuel speculation about co-formulations with other HIV drugs, including ViiV's Epzicom and Gilead's Truvada.

ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III

Phase II results presented at International AIDS Society meeting fuel speculation about co-formulations with other HIV drugs, including ViiV's Epzicom and Gilead's Truvada.

Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns

The four-drug combination pill for HIV has significant sales potential, and will be a mainstay for Gilead to protect its leadership in the market, but with two novel components there is still much work to be done.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel